New drug TUB-030 targets Hard-to-Treat cancers in early trial

NCT ID NCT06657222

Recruiting now Disease control Sponsor: Tubulis GmbH Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TUB-030 (an antibody-drug conjugate targeting 5T4 protein)
What this could lead to: If successful, this could lead to a new treatment option for several advanced solid cancers that are hard to treat.
What could go wrong: This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or may have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal carcinoma Head and Neck Neoplasms head and neck squamous cell carcinoma neoplasm non-small cell lung carcinoma small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CRC HNSCC NSCLC SCLC TNBC - TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Arensia Exploratory Medicine
RECRUITING

Bucharest, Romania
Arensia Exploratory Medicine
RECRUITING

Cluj-Napoca, Romania
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Clinica Uni de Navara
RECRUITING

Madrid, Spain
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Hospital Clinic Barcelona
RECRUITING

Barcelona, Spain
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
Mount Sinai
RECRUITING

New York, New York, 11766, United States
NEXT Oncology - Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
NEXT Oncology Austin
RECRUITING

Austin, Texas, 78758, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Princess Margaret
RECRUITING

Toronto, Canada
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Washington University
RECRUITING

St Louis, Missouri, 63130, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.